Clinical Relevance of Typing HLA-DR7-DQ2

Corporacion Parc Tauli92 enrolled

Overview

Celiac disease patients with HLA-DR7-DQ2 haplotype have the same histological, analytical and clinical behaviour as patients with HLA-DR3-DQ2 haplotype.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Celiac Disease Patients Following Recommendations of ESPGHAN HLA-DQ2 Typing Include HLA-DR7-DQ2 Haplotypes

Interventions

There is not any interventionOTHER

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of celiac disease following ESPGHAN recommendations * HLA-DQ2 typing including HLA-DR3-DQ2 and HLA-DR7-DQ2 haplotypes Exclusion Criteria: * Patients who have not been diagnosed for celiac disease * HLA-DQ2 typing that not include HLA-DR7-DQ2 haplotype

Locations (1)

Corporació Sanitària i Universitària Parc Taulí

Sabadell, Barcelona, Spain

Outcomes

Primary Outcomes

Anti-tissue transglutaminase

Time frame: Up to 1 month after diagnosis

Secondary Outcomes

Anti-Endomysium autoantibodies

Time frame: Up to 1 month after diagnosis

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.